medigraphic.com

2020, Number 4

<< Back Next >>

Rev Mex Anest 2020; 43 (4)

Perioperative management of the patient with COVID-19 coagulopathy

Oriol-López SA

Language: Spanish
References: 24
Page: 257-263
PDF size: 294.05 Kb.


ABSTRACT

The appearance of the SARS-CoV-2 coronavirus disease, in China late 2019, has spread rapidly to become a pandemic, the clinical characteristics which range from being asymptomatic to having the severe form, where patients present abnormalities of the Coagulation, generally a hypercoagulable state, may evolve to disseminated intravascular coagulation, multiple organ failure, and / or death. It is important to investigate comorbidities; verify the coagulation status from the first contact, analyzing the routes: endogenous, exogenous, common, fibrinolytic system and platelet count, using technology like thromboelastography and sonoclot. The use of anticoagulants is indicated, it can be used unfractionated or low molecular weight heparin, with laboratory tests to adjust the dose, in order to avoid states of hypocoagulability, use blood products when necessary. Remember that antiviral treatment can have interactions with anticoagulants, especially oral ones, bleeding is not common. There are occlusion problems of installed catheters, one must avoid frequent of these washing with heparin. If the patient requires an emergency surgical or invasive procedure, it must verify the evolution of the coagulation, if it cannot be postponed, use treatment with blood products according to the alteration detected. Follow the management algorithm in the operating room to avoid infections from health personnel.


REFERENCES

  1. Joly BS, Siguret V, Veyradier A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID 19. Intensive Care Medicine. 2020. https://doi.org/10.1007/s00134-020-06088-1.

  2. Debuc B, Smadja DM. Is COVID-19 a new hematologic disease? Stem Cell Rev and Rep. 2020. https://doi.org/10.1007/s12015-020-09987-4.

  3. Fan BE, Chia YW, Lin SC, Kuperan P, Wei CS, Ling LM, et al. Global haemostatic tests in rapid diagnosis and management of COVID 19 associated coagulopathy in acute limb ischaemia. J Thromb Thrombolysis. 2020:1-6. https://doi.org/10.1007/s11239-020-02165-w.

  4. Joly BS, Siguret V, Veyradier A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID 19. Intensive Care Medicine. 2020. https://doi.org/10.1007/s00134-020-06088-1.

  5. Song JC, Wang G, Zhang W, Zhang Y, Wei-Qin Li W-C, Zhou Z. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID19. Military Med Res. 2020;7. https://doi.org/10.1186/s40779-020-00247-7.

  6. Wujtewicz MA, Dylczyk-Sommer A, Aszkiełowicz A, Zdanowski S, Piwowarczyk S, Owczuk R. COVID-19. ¿What should anaethesiologists and intensivists know about it? Anaesthesiol Intensive Ther. 220;52:34-41. https://doi.org/10.5114/ait.2020.93756.

  7. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. Journal of Thrombosis and Haemostasis 2020. doi: 10.1111/jth.14810.

  8. Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et al. Hypercoagulability of COVID-19 patients in Intensive Care Unit. a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020. doi doi: 10.1111/JTH.14850.

  9. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Marianna PM, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95:834-847. doi: 10.1002/ajh.25829.

  10. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 202018:1094-1099. doi: 10.1111/JTH.14817.

  11. Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood. 2018;131:845-854.

  12. Thachil J. The versatile heparin in COVID-19. J Thromb Haemost. 2020;18:1020-1022. doi: 10.1111/jth.14821.

  13. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135:2033-2040.

  14. Bikdeli B, Madhavan MV, Jiménez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. Journal of the American College of Cardiology. 2020;75:2950-2973. https://doi.org/10.1016/j.jacc.2020.04.031.

  15. Baron DM, Franchini M, Goobie SM, Javidroozi M, Klein AA, Lasocki S, et al. Patient blood management during the COVID-19 pandemic: a narrative review. Anesthesia 2020. doi: 10.1111/anae.15095.

  16. Galluccio F, Ergonenc T, Garcia MA, El-Sayed AA, Pérez-Herrero M, Aguilar R, et al. Treatment algorithm for COVID-19: a multidisciplinary point of view. https://doi.org/10.1007/s10067-020-05179-0.

  17. Thachil J, Agarwal S. Understanding the COVID-19 coagulopathy spectrum. doi: 10.1111/anae.15141.

  18. Harzallah I, Debliquis A, Drénou B. Frequency of lupus anticoagulant in Covid-19 patients. J Thromb Haemost. 2020. doi: 10.1111/JTH.14937.

  19. Vlachodimitropoulou KE, Vivanti AJ, Shehata N, Benachi A, Le Gouez A, Desconclois C, et al. COVID-19 and acute coagulopathy in pregnancy. doi: 10.1111/jth.14856.

  20. Vivas D, Roldán I, Ferrandis R, Marín F, Roldán V, Tello-Montoliu A, et al. Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU. Rev Esp Cardiol. 2018;71:553-564.

  21. Oprea AD, Noto CJ, Halaszynski TM. Risk stratification, perioperative and periprocedural management of the patient receiving anticoagulant therapy. J Clin Anesth. 2016;34:586-599.

  22. Canonico ME, Siciliano R, Scudiero F, Sanna GD, ParodiM G. The tug-of-war between coagulopathy and anticoagulant agents in patients with COVID-19. Eur Heart J Cardiovasc Pharmacother. 2020. doi: 10.1093/ehjcvp/pvaa048.

  23. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with por prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844-847.

  24. Cecconi M, Forni G, Mantovani A. Ten things we learned about COVID 19. Intensive Care Med. 2020;1-4. https://doi.org/10.1007/s00134-020-06140-0.




2020     |     www.medigraphic.com